Multiple System Atrophy Market to Reach US$ 213.9 Mn by 2032

The Multiple System Atrophy (MSA) market, estimated to reach USD 155.1 million in 2025, is projected to grow to USD 213.9 million by 2032, registering a steady compound annual growth rate (CAGR) of 4.7% during the forecast period. This growth is primarily fueled by the increasing awareness of rare neurodegenerative disorders, advancements in diagnostic techniques, and a growing patient pool due to improved detection rates. Additionally, rising R&D efforts aimed at disease-modifying therapies, along with a growing pipeline of clinical-stage candidates, are driving the market interest. The expanding role of biomarker research, combined with increased funding from both governmental and private sectors, further supports the development of effective treatments. As the unmet medical need for MSA remains high, pharmaceutical companies and research institutions are intensifying efforts to bring novel therapeutics to the market, bolstering future growth prospects.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/multiple-system-atrophy-msa-market

The multiple system atrophy (MSA) market is experiencing steady growth, driven by rising awareness of rare neurodegenerative disorders, advancements in neuroimaging and diagnostic technologies, and increased R&D investment in disease-modifying therapies. In the absence of a definitive cure, the market remains focused on symptomatic relief, fostering continued research into both pharmacological and non-pharmacological interventions. The growing prevalence of neurodegenerative diseases, particularly among aging populations, is further amplifying the need for early diagnosis and multidisciplinary care strategies.

In May 2023, Alterity Therapeutics announced the initiation of a Phase 2 clinical trial of ATH434 in patients with MSA, enrolling its first patient as part of efforts to evaluate biomarker and imaging endpoints alongside clinical outcomes. This trial reflects a broader shift toward targeted, disease-modifying approaches in the treatment of MSA.

Moreover, expanding access to high-resolution neuroimaging, the emergence of novel fluid and imaging biomarkers (such as neurofilament light chain and brain iron levels), and increased collaboration between academic centers and pharmaceutical companies are driving diagnostic and therapeutic innovation. Regulatory incentives for rare diseases—including orphan drug designations, fast-track approvals, and research grants—continue to encourage the development of new treatment modalities.

However, the market faces notable challenges, including diagnostic complexity due to clinical overlap with Parkinson’s disease and other atypical parkinsonian syndromes, limited awareness among general practitioners, and a lack of validated biomarkers for early detection. High treatment costs and limited therapeutic efficacy of current options further constrain patient outcomes.

Despite these hurdles, the MSA market is poised for incremental growth, underpinned by advancements in neuroscience, strategic industry collaborations, and a strong pipeline of investigational drugs aiming to address the significant unmet medical need in this rare and debilitating condition.

There is a growing trend toward holistic, team-based care approaches in managing MSA, integrating neurologists, physiotherapists, speech therapists, occupational therapists, and mental health professionals. These models aim to improve quality of life, slow functional decline, and address the complex motor and non-motor symptoms of MSA more effectively than traditional siloed care pathways.

In January 2024, The Multiple System Atrophy Coalition launched its 2023 network of MSA Centers of Excellence, comprising top-tier institutions like Mayo Clinic, Stanford, and Vanderbilt—all equipped with dedicated multidisciplinary teams (neurologists, physiotherapists, speech and occupational therapists, mental health professionals) to provide comprehensive, holistic care for patients and families.

The adoption of digital tools such as gait analysis apps, wearable sensors for tracking autonomic dysfunction, and AI-assisted motor symptom monitoring is gaining traction in MSA management. These technologies offer real-time, remote patient monitoring, enabling better disease progression tracking and personalized interventions.

In October 2024, preprint study demonstrated that wearable accelerometers on wrists/ankles, coupled with machine learning, accurately captured motor dysfunction and disease progression in adult ataxias, including MSA-C. Longitudinal submovement data correlated strongly with clinical severity measures, showcasing how remote sensor-based monitoring can reflect real-world disease dynamics.

As biomarker research in MSA (especially involving α-synuclein and iron accumulation) advances, there is an emerging opportunity for the co-development of companion diagnostics. These diagnostics can support personalized medicine approaches, helping identify suitable patient subgroups for investigational drugs and improving trial stratification, regulatory acceptance, and treatment outcomes.

In June 2021, the European Medicines Agency provided guidance supporting the use of biomarker endpoints—specifically iron imaging and α-synuclein biomarkers—for patient selection in ATH434 trials. This regulatory acknowledgment marks progress toward formalizing companion diagnostic frameworks alongside therapy development.

Governments and academic institutions are forming public–private partnerships to build infrastructure, patient registries, and collaborative research networks for rare diseases like MSA. These initiatives can accelerate data generation, natural history studies, and real-world evidence (RWE) collection, crucial for guiding regulatory pathways, post-marketing surveillance, and payer reimbursement strategies.

In January 2023, PharmaKure, a U.K. biotech focused on proteinopathies, partnered with the MSA Trust and University College London to co-sponsor an MSA research symposium aimed at biomarker development and early diagnostic testing. Their collaboration enabled access to clinical samples and supported early-stage research on oligomeric biomarkers.